552 related articles for article (PubMed ID: 23072512)
41. Hormone receptor expression is associated with a unique pattern of metastatic spread and increased survival among HER2-overexpressing breast cancer patients.
Paluch-Shimon S; Ben-Baruch N; Wolf I; Zach L; Kopolovic J; Kruglikova A; Modiano T; Yosepovich A; Catane R; Kaufman B
Am J Clin Oncol; 2009 Oct; 32(5):504-8. PubMed ID: 19564785
[TBL] [Abstract][Full Text] [Related]
42. Adjuvant chemotherapy for the treatment of HER2-positive early breast cancer.
Clavarezza M; Venturini M
Oncology; 2009; 77 Suppl 1():14-7. PubMed ID: 20130427
[TBL] [Abstract][Full Text] [Related]
43. [Retrospective analysis of trastuzumab treatment in 141 patients with Her-2 positive breast cancer].
Wang Y; Li JJ; DI GH; Lu JS; Wu J; Liu GY; Hu XC; Wang ZH; Yang WT; Shao ZM
Zhonghua Zhong Liu Za Zhi; 2010 Nov; 32(11):864-7. PubMed ID: 21223695
[TBL] [Abstract][Full Text] [Related]
44. Everolimus: a new hope for patients with breast cancer.
Sendur MA; Zengin N; Aksoy S; Altundag K
Curr Med Res Opin; 2014 Jan; 30(1):75-87. PubMed ID: 24050600
[TBL] [Abstract][Full Text] [Related]
45. Use of pertuzumab for the treatment of HER2-positive metastatic breast cancer.
De Mattos-Arruda L; Cortes J
Adv Ther; 2013 Jul; 30(7):645-58. PubMed ID: 23881722
[TBL] [Abstract][Full Text] [Related]
46. Pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.
Kawajiri H; Takashima T; Kashiwagi S; Noda S; Onoda N; Hirakawa K
Expert Rev Anticancer Ther; 2015 Jan; 15(1):17-26. PubMed ID: 25494663
[TBL] [Abstract][Full Text] [Related]
47. [Efficacy and prognostic analysis of retreatment with trastuzumab-based therapy after multi-line targeted therapy resistance in HER2-positive metastatic breast cancer].
Bian L; Jiang ZF; Wang T; Song JJ; Guo YF; Zhang HQ; Zhang SH; Wu SK; Song ST
Zhonghua Yi Xue Za Zhi; 2013 Jan; 93(1):48-52. PubMed ID: 23578455
[TBL] [Abstract][Full Text] [Related]
48. Importance of confirming HER2 overexpression of recurrence lesion in breast cancer patients.
Nakamura R; Yamamoto N; Onai Y; Watanabe Y; Kawana H; Miyazaki M
Breast Cancer; 2013 Oct; 20(4):336-41. PubMed ID: 22367960
[TBL] [Abstract][Full Text] [Related]
49. [Pertuzumab (Perjeta®) approval in HER2-positive metastatic breast cancers].
Sabatier R; Gonçalves A
Bull Cancer; 2014; 101(7-8):765-71. PubMed ID: 25091659
[TBL] [Abstract][Full Text] [Related]
50. Pertuzumab in HER2-positive breast cancer.
Sendur MA; Aksoy S; Altundag K
Curr Med Res Opin; 2012 Oct; 28(10):1709-16. PubMed ID: 22953713
[TBL] [Abstract][Full Text] [Related]
51. Trastuzumab in small tumours and in elderly women.
Albanell J; Ciruelos EM; Lluch A; Muñoz M; Rodríguez CA
Cancer Treat Rev; 2014 Feb; 40(1):41-7. PubMed ID: 23659993
[TBL] [Abstract][Full Text] [Related]
52. [Chinese HER2 positive early breast cancer trastuzumab adjuvant therapy: preliminary outcomes].
Zhang P; Yu SY; Shen ZZ; Song ST; Guan ZZ; Jiao SC; Zheng S; Xu GW; Feng FY
Zhonghua Yi Xue Za Zhi; 2012 Dec; 92(47):3345-9. PubMed ID: 23328596
[TBL] [Abstract][Full Text] [Related]
53. Ado-trastuzumab emtansine (T-DM1): a novel antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer.
Baron JM; Boster BL; Barnett CM
J Oncol Pharm Pract; 2015 Apr; 21(2):132-42. PubMed ID: 24682654
[TBL] [Abstract][Full Text] [Related]
54. Generation of HER2-specific antibody immunity during trastuzumab adjuvant therapy associates with reduced relapse in resected HER2 breast cancer.
Norton N; Fox N; McCarl CA; Tenner KS; Ballman K; Erskine CL; Necela BM; Northfelt D; Tan WW; Calfa C; Pegram M; Colon-Otero G; Perez EA; Clynes R; Knutson KL
Breast Cancer Res; 2018 Jun; 20(1):52. PubMed ID: 29898752
[TBL] [Abstract][Full Text] [Related]
55. [Small HER2-positive breast cancer: which prognosis and which adjuvant treatment?].
Gonçalves A; Vassilakopoulou M; Spano JP
Bull Cancer; 2013 Sep; 100(9):847-56. PubMed ID: 23899689
[TBL] [Abstract][Full Text] [Related]
56. Everolimus and its role in hormone-resistant and trastuzumab-resistant metastatic breast cancer.
Keck S; Glencer AC; Rugo HS
Future Oncol; 2012 Nov; 8(11):1383-96. PubMed ID: 23148612
[TBL] [Abstract][Full Text] [Related]
57. Trastuzumab and survival of patients with metastatic breast cancer.
Kast K; Schoffer O; Link T; Forberger A; Petzold A; Niedostatek A; Werner C; Klug SJ; Werner A; Gatzweiler A; Richter B; Baretton G; Wimberger P
Arch Gynecol Obstet; 2017 Aug; 296(2):303-312. PubMed ID: 28616827
[TBL] [Abstract][Full Text] [Related]
58. Treatment of trastuzumab-refractory, HER2-positive metastatic breast cancer.
Hurvitz S
Clin Adv Hematol Oncol; 2014 Apr; 12(4):260-2. PubMed ID: 25003356
[No Abstract] [Full Text] [Related]
59. Systemic therapy for early-stage HER2-positive breast cancers: time for a less-is-more approach?
Paplomata E; Nahta R; O'Regan RM
Cancer; 2015 Feb; 121(4):517-26. PubMed ID: 25346473
[TBL] [Abstract][Full Text] [Related]
60. High HER2 expression correlates with response to the combination of lapatinib and trastuzumab.
Scaltriti M; Nuciforo P; Bradbury I; Sperinde J; Agbor-Tarh D; Campbell C; Chenna A; Winslow J; Serra V; Parra JL; Prudkin L; Jimenez J; Aura C; Harbeck N; Pusztai L; Ellis C; Eidtmann H; Arribas J; Cortes J; de Azambuja E; Piccart M; Baselga J
Clin Cancer Res; 2015 Feb; 21(3):569-76. PubMed ID: 25467182
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
